Innovative nasal vaccines to prevent pathogen colonization and infection in the upper respiratory tract
The recently signed NOSEVAC project, coordinated by the European Vaccine Initiative (EVI), aims to cultivate and evaluate inventive nasal vaccine platforms as an innovative approach to prevent early stage infection, thereby inhibiting upper respiratory tract (URT) colonisation, transmission, and disease.
The project consortium consists of 12 prestigious partners from the EU, the UK and Switzerland, of which the University of Geneva and the University Hospitals of Geneva (HUG) are part of. Professor Arnaud Didierlaurent, a member of the GCIR, is the principal investigator collaborating in the consortium at UNIGE. The HUG clinicians involved are Dr Arnaud L'huillier, Dr Virginie Prendki and Prof Jacques Schrenzel.
The consortium has a length of 5-years and a budget of € 11.1 Mio (with € 6.8 Mio from EU.
Learn more about this new initiative on the following news release.
PROJECT PARTNERS:
1. Epithelix
2. Erasmus MC -department of Viroscience
3. INSERM
4. Institut Pasteur de Lille
5. Istituto Superiore di Sanità (ISS)
6. Quantoom Biosciences
7. University of Geneva
8. University of Lille 1 Sciences and Technology
9. University of Oxford
10. University of Lausanne - UNIL
11. Universidad de Santiago de Compostela
12. Veterna S.r.l.